PHARMACOVIGILANCE: A TEACHER’S COMPREHENSIVE GUIDE
Welcome, future pharmacovigilance professionals and healthcare experts!
The historical development of the word “Pharmacovigilance” includes the Greek word pharmacon meaning ‘drug’ or ‘medicinal substance’ and the Latin word vigilare meaning ‘to keep watch’. Pharmacovigilance is essentially the science of watching over the safety of medicines—a responsibility that has become increasingly critical in modern healthcare.
As a pharmacy educator with years of experience teaching drug safety and pharmacovigilance, I have observed that students often underestimate the importance of this field. The tragic history of drug disasters—from the sulfanilamide elixir tragedy to the thalidomide catastrophe—has taught us that drug safety monitoring is not optional; it is essential. Pharmacovigilance is the systematic activity that has significant social and economic ramifications, designed to evaluate medication risk/benefit ratios while enhancing patient safety and quality of life.
In this comprehensive guide, I will walk you through the definition, aims, scope, history, and significance of pharmacovigilance. By the end of this article, you will have a thorough understanding of why pharmacovigilance is the cornerstone of patient safety in healthcare. Let us begin our journey into the critical field of drug safety monitoring.
Dpharmguru’s exam insights:
Pharmacovigilance is a frequently tested topic in pharmacy exams. Remember: According to WHO, pharmacovigilance is defined as “the science and activities concerned with the detection, assessment, understanding and prevention of adverse reactions to medicines.” Key concepts include: ADR reporting, spontaneous reporting systems, the history of pharmacovigilance (thalidomide tragedy, sulfanilamide tragedy), and the scope of pharmacovigilance in various areas like herbal medicine, disease control programmes, and blood banks. Pay special attention to the thalidomide tragedy—it is a landmark event in pharmacovigilance history!
11.1. PHARMACOVIGILANCE
11.1.1. Definition
The historical development of the word “Pharmacovigilance” includes the Greek word pharmacon = ‘drug’ or ‘medicinal substance’ and the Latin word vigilare = ‘to keep watch’.
According to the World Health Organization (WHO), pharmacovigilance has been defined as “the science and activities concerned with the detection, assessment, understanding and prevention of adverse reactions to medicines” (particularly long-term and short-term adverse effects).
The European Commission (EU) defines pharmacovigilance as “the science and process to monitor the safety of medicinal drugs and take actions for increasing the benefits and reducing risks of medicines.”
11.1.2. Aims of Pharmacovigilance
- To improve patient care and safety associated with the use of medicines as well as all medical and paramedical interventions.
- To improve public health and safety associated with the use of medicines.
- To identify complications associated with the use of medicines and convey them in an appropriate manner.
- To evaluate advantage, efficacy and risk of medicines as well as promoting safe, rational and more effective (including cost-effective) use of these drugs.
- To encourage education, understanding and clinical training in pharmacovigilance along with its effective communication to healthcare workers and the public.
11.1.3. Scope of Pharmacovigilance
There are several areas where pharmacovigilance plays a very critical role in providing safety from toxic effects of therapeutic drugs:
1. Herbal Medicine
The safety and efficacy of herbal medicines has become a key concern to both the general public and national health authorities. However, the use of herbal plants in traditional and ancient medicine systems continues to expand rapidly all over the world. People are shifting towards herbal medicinal systems for the treatment of various diseases. Pharmacovigilance plays a crucial role in monitoring the safety of these herbal products.
2. Disease Control Public Health Programmes
The major concern today in countries having no safety monitoring or regulatory system (pharmacovigilance) or in remote areas having few or no healthcare surveillance is monitoring the safety of medicines. The primary problem occurs in specific communities where the use of medicines becomes difficult—for example, treatment of tropical diseases such as leishmaniasis, malaria, schistosomiasis, tuberculosis, and HIV/AIDS. Pharmacovigilance must be a priority for every country with a public health disease control programme.
3. Ecopharmacovigilance
Adverse drug reactions related to drugs within the ecosystem with all consequences in human beings and other organisms in the environment are included in ecopharmacovigilance. Examples include:
- Patient excretion of drugs or their metabolites through the sewage system.
- Hospital or self-disposal of unused, expired or unwanted drugs through flushing or trash.
- Direct release of drugs and its byproducts from manufacturing units into the waste water system.
- Terrestrial deposition from solid waste landfills and sludge application to lands.
- Rapid breakdown of acetylsalicylic acid leading to deposition in lands.
- Clofibric acid (active metabolite of clofibrate) detected in drinking water.
- Fluoroquinolone (fat-soluble and stable drug) absorbed to sludge particles through sewage treatment.
4. Blood Bank
In blood banks, pharmacovigilance plays an important role by keeping a record of all donors donating blood, their health safety data, etc. For example, if a person who has suffered from dengue fever in the past donates blood and any type of adverse reaction is observed in the patient receiving the same blood, the pharmacovigilance team keeps a record of the adverse drug reaction.
5. Immunisation and Vaccination
Pharmacovigilance plays a crucial role in vaccination. When serious adverse reactions are observed after vaccination or when the dosage form gets changed, any adverse event must be checked from time to time. For example, the polio vaccine was initially given as polio drops, but recently manufacturers changed the dosage form to injectable. After vaccination, the site of injection must be monitored for inflammation, thrombosis, or other skin reactions.
6. Dermatology
In order to monitor any type of skin reactions or adverse events related to skin diseases, pharmacovigilance plays an important role in the area of dermatology.
11.2. OVERVIEW OF PHARMACOVIGILANCE
Approximately 170 years ago, pharmacovigilance began, though it was not yet known by that name. It is a systematic activity in the medical field that has significant social and economic ramifications and is meant to evaluate medication risk/benefit ratios while enhancing patient safety and quality of life.
11.2.1. History and Development of Pharmacovigilance
The history and development of pharmacovigilance is marked by several key milestones:
- 1848 (January 29): The first milestone in pharmacovigilance history—a young girl (Hannah Greener) in north England died after receiving anesthesia (chloroform) before an infected toenail was removed. The cause of death was investigated as pulmonary aspiration or lethal arrhythmia.
- 1937: The use of sulfanilamide elixir containing diethyl glycol as a solvent resulted in the death of 107 people in the USA. The solvent was found to be responsible for the deaths, highlighting the need for safety testing of excipients.
- 1938: Douthwaite suggested that Acetylsalicylic Acid (ASA) is responsible for causing melena. In 1955, studies proved that ASA could cause gastrointestinal diseases, and patients with gastrointestinal ulcers were contraindicated.
- 1961: The Thalidomide Tragedy made a milestone in the origin and development of pharmacovigilance. The drug was prescribed to pregnant women as a harmless treatment for nausea and morning sickness. The drug was tested in about 300 patients without any prior toxicity studies. Australian doctor Dr. McBride suggested the correlation between congenital malformation of babies and thalidomide, which caused phocomelia—a condition involving malformations of babies’ arms and legs resulting in seal-like limbs. The drug was discontinued in 1962 after it was reported under pharmacovigilance.
Pharmacovigilance in India
- 1986: Pharmacovigilance in India was introduced with the formal introduction of Adverse Drug Reaction (ADR) monitoring system under the guidance of the Drug Controller of India. The main purpose was to generate data on adverse reactions through spontaneous reporting. It consisted of 12 main centers covering populations of about 50 million each.
- 1997: A significant revision took place—India became a part of the WHO Program for International Drug Monitoring controlled by the Uppsala Monitoring Centre in Sweden.
- 2005 (January 1): The National Pharmacovigilance Programme of India (PvPI) was launched, sponsored by WHO and funded by the World Bank. The program was officially constituted on 23 November 2004 with World Bank funding of 0.1 million USD annually for 5 years.
- National Pharmacovigilance Advisory Committee: Located at the office of the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India helps coordinate ADR reporting. The country’s ADR reports flow into two main centers:
- South West Zonal Centre: Department of Clinical Pharmacology, King Edward VII Memorial Hospital, Mumbai
- North East Zonal Centre: Department of Pharmacology, All India Institute of Medical Sciences, New Delhi
11.2.2. Significance of Pharmacovigilance
Pharmacovigilance encompasses the following:
- Drug Surveillance: This is the drug safety monitoring process. Surveillance starts when the drug is approved for market use after successful completion of clinical trials.
- Adverse Effects of Pharmaceutical Formulations: Pharmacovigilance highly focuses on adverse drug reactions (ADRs), which significantly reduces the chances of drug toxicity in pharmaceutical formulations.
- Adverse Drug Reaction Reporting: Organised in pharmacovigilance to protect human health and life by the detection, analysis, and prevention of ADRs and other drug-related problems.
- Postmarketing Legislation: Strengthens the legal basis for requesting post-authorisation safety studies (PASSs) and post-authorisation efficacy studies (PAESs) from the pharmaceutical industry.
Dpharmguru’s exam insights:
The history of pharmacovigilance is frequently tested in exams. Remember these key milestones: 1848 (Hannah Greener’s death from chloroform), 1937 (Sulfanilamide elixir tragedy), 1961 (Thalidomide tragedy), 1964 (The Yellow Card system in the UK), 1968 (WHO Programme for International Drug Monitoring), and 2005 (India’s PvPI). The Thalidomide tragedy is the most significant event—it led to the establishment of modern pharmacovigilance systems worldwide!
KEY MILESTONES IN PHARMACOVIGILANCE HISTORY
| Year | Event | Significance |
|---|---|---|
| 1848 | Hannah Greener’s death from chloroform | First recorded adverse reaction |
| 1937 | Sulfanilamide elixir tragedy (107 deaths) | Highlighted need for excipient safety testing |
| 1938 | ASA linked to melena/GI diseases | First recognition of drug-induced GI toxicity |
| 1961 | Thalidomide tragedy (phocomelia) | Led to modern pharmacovigilance systems |
| 1964 | Yellow Card system in the UK | First national ADR reporting system |
| 1968 | WHO Programme for International Drug Monitoring | Global pharmacovigilance network |
| 1986 | ADR monitoring introduced in India | Beginning of pharmacovigilance in India |
| 2005 | PvPI launched in India | National Pharmacovigilance Programme of India |
PHARMACOVIGILANCE IN INDIA: KEY ORGANISATIONS
| Organisation | Role |
|---|---|
| CDSCO | Central Drugs Standard Control Organisation – National Regulatory Authority |
| PvPI | National Pharmacovigilance Programme of India |
| WHO-UMC | Uppsala Monitoring Centre – International Drug Monitoring |
| South West Zonal Centre | KEM Hospital, Mumbai – ADR reporting center |
| North East Zonal Centre | AIIMS, New Delhi – ADR reporting center |
FREQUENTLY ASKED QUESTIONS (FAQs)
1. What is the difference between pharmacovigilance and pharmacoepidemiology?
Pharmacovigilance focuses on the detection, assessment, understanding, and prevention of adverse drug reactions. Pharmacoepidemiology is the study of the use and effects of drugs in large populations. Pharmacoepidemiology provides the methods and tools used in pharmacovigilance research.
2. What was the Thalidomide tragedy?
The Thalidomide tragedy occurred in 1961 when the drug thalidomide, prescribed to pregnant women for nausea, caused severe birth defects (phocomelia—seal-like limbs) in thousands of babies worldwide. This led to the establishment of modern pharmacovigilance systems.
3. What is the WHO definition of pharmacovigilance?
According to WHO, pharmacovigilance is defined as “the science and activities concerned with the detection, assessment, understanding and prevention of adverse reactions to medicines.”
4. What is the Uppsala Monitoring Centre (UMC)?
The Uppsala Monitoring Centre (UMC) in Sweden is the WHO Collaborating Centre for International Drug Monitoring. It maintains the global database of individual case safety reports (ICSRs) from member countries, including India.
5. What is the Yellow Card system?
The Yellow Card system was established in the UK in 1964 as the first national ADR reporting system. Healthcare professionals and patients can report suspected adverse drug reactions using yellow cards, which are then collected and analyzed by the regulatory authorities.
6. What is ecopharmacovigilance?
Ecopharmacovigilance is the study of adverse drug reactions related to drugs within the ecosystem—including consequences in human beings and other organisms. It covers drug excretion, disposal of unused drugs, release of drug byproducts from manufacturing units, and contamination of water systems with drug metabolites.
7. What are the aims of pharmacovigilance?
The aims of pharmacovigilance include improving patient care and safety, improving public health safety, identifying drug-related complications, evaluating risk-benefit ratios, and encouraging education and training in drug safety monitoring.
SUMMARY
Pharmacovigilance is the science of drug safety monitoring that has evolved significantly over the past 170 years. From the tragic death of Hannah Greener in 1848 to the devastating thalidomide tragedy of 1961, history has taught us the critical importance of monitoring drug safety throughout the lifecycle of medicines.
The scope of pharmacovigilance is vast and continues to expand—covering herbal medicines, disease control programmes, ecopharmacovigilance, blood banks, immunisation, and dermatology. Ecopharmacovigilance is an emerging area that addresses the environmental impact of drugs, including contamination of water systems, soil, and the broader ecosystem.
In India, pharmacovigilance has come a long way—from the introduction of ADR monitoring in 1986 to the launch of the National Pharmacovigilance Programme of India (PvPI) in 2005. The WHO Programme for International Drug Monitoring and the Uppsala Monitoring Centre provide global coordination and support for pharmacovigilance activities worldwide.
As I always tell my students: “Pharmacovigilance is not just a regulatory requirement—it is a moral obligation. Every pharmacist has a responsibility to monitor drug safety and report adverse reactions. Your vigilance can save lives.”
REFERENCES AND FURTHER READING
- World Health Organization (WHO). (2022). Pharmacovigilance: Guidelines and Standards. Retrieved from https://www.who.int.
- Uppsala Monitoring Centre (UMC). (2022). WHO Programme for International Drug Monitoring. Retrieved from https://www.who-umc.org.
- Central Drugs Standard Control Organisation (CDSCO). (2022). Pharmacovigilance Programme of India (PvPI). Government of India.
- International Conference on Harmonisation (ICH). (2022). E2E Pharmacovigilance Planning Guidelines. Retrieved from https://www.ich.org.
- Pharmacy Council of India (PCI). (2022). Pharmacovigilance Guidelines for Pharmacy Practice. New Delhi: PCI.
- European Medicines Agency (EMA). (2022). Pharmacovigilance Legislation and Guidelines. Retrieved from https://www.ema.europa.eu.
Disclaimer: This article is for educational purposes only and does not constitute medical advice. Pharmacovigilance regulations and guidelines may vary by region—always refer to your local regulatory authorities for specific requirements.
written by:
Dr. N. Sujith Kumar
For More Study Materials, Visit: www.dpharmguru.com
